Skip to content
Aldesleukin
Proleukin (aldesleukin) is a protein pharmaceutical. Aldesleukin was first approved as Proleukin on 1992-05-05. It is used to treat colorectal neoplasms, HIV infections, melanoma, multiple myeloma, and non-hodgkin lymphoma amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Proleukin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Aldesleukin
Tradename
Proper name
Company
Number
Date
Products
ProleukinaldesleukinClinigen, Inc.N-103293 RX1992-05-05
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
proleukinBiologic Licensing Application2020-12-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasms—D015179—
hiv infectionsEFO_0000764D015658B20
melanoma—D008545—
multiple myeloma—D009101C90.0
non-hodgkin lymphoma—D008228C85.9
renal cell carcinomaEFO_0000376D002292—
Agency Specific
FDA
EMA
Expiration
Code
aldesleukin, Proleukin, Clinigen, Inc.
2105-01-09Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AC: Interleukins
— L03AC01: Aldesleukin
HCPCS
Code
Description
J9015
Injection, aldesleukin, per single use vial
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic conjunctivitisD003233EFO_0007141H10.44——54110
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALDESLEUKIN
INNaldesleukin
Description
Proleukin (aldesleukin) is a protein pharmaceutical. Aldesleukin was first approved as Proleukin on 1992-05-05. It is used to treat colorectal neoplasms, HIV infections, melanoma, multiple myeloma, and non-hodgkin lymphoma amongst others in the USA. New value
Classification
Protein
Drug classinterleukins: interleukin-2 analogues and derivatives
Image (chem structure or protein)ALDESLEUKIN
Structure (InChI/SMILES or Protein Sequence)
>5LQB:H|anti-hIL2 FAB fragment heavy chain QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAY MQLSSLTSDDSAVYFCARWRGDGYYAYFDVWGAGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTL TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPT >5LQB:L|anti-hIL2 FAB fragment light chain DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIH PVEEEDAATYYCQQSNEDPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQ NGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
Identifiers
PDB1M47, 1M48, 1M49, 1M4A, 1M4B, 1M4C, 1NBP, 1PW6, 1PY2, 1QVN, 1Z92, 2B5I, 2ERJ, 5LQB
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201438
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDM89N0Q7EQR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,892 documents
View more details
Safety
Black-box Warning
Black-box warning for: Proleukin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
559 adverse events reported
View more details